Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (91,940,882)	$ (58,725,412)	$ (31,703,433)
Net loss attributable to non-controlling interests		95,222	560,144
NET LOSS ATTRIBUTABLE TO ARROWHEAD	(91,940,882)	(58,630,190)	(31,143,289)
Loss from discontinued operations			354
(Gain) loss on disposal of fixed assets	(19,195)	58,878	76,388
Change in value of derivatives	(2,869,267)	6,033,659	5,300,389
Contingent consideration - Fair Value Adjustments	1,891,533	2,375,658	1,421,652
Acquired in-process research and development	10,142,786
Stock-based compensation	10,232,897	5,696,173	1,536,271
Depreciation and amortization	2,336,207	1,345,655	1,751,412
Amortization of note premiums	1,110,524	793,887	128,406
Gain on debt extinguishment		(84,721)
Noncash gain in equity investment		(87,197)
Noncash impairment expense		2,172,387	2,315,721
Non-controlling interest		(95,222)	(560,144)
Changes in operating assets and liabilities:
Receivables		75,000	(65,625)
Other receivables	(789,090)	(25,867)	1,080
Prepaid expenses	(2,693,839)	(15,812)	44,713
Other current assets	(2,492)	(13,287)	(1,811)
Accounts payable	2,497,804	1,412,275	321,647
Accrued expenses	4,435,784	3,478,094	27,920
Other	(40,385)	94,257	(187,910)
NET CASH USED IN OPERATING ACTIVITIES	(65,707,615)	(35,416,373)	(19,032,826)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash paid for acquisitions	(10,000,000)
Purchases of property and equipment	(1,970,612)	(1,717,362)	(296,880)
Proceeds from sale of fixed assets	500	10,000	89,505
Purchase of marketable securities		(46,365,528)	(10,732,571)
Proceeds from sale of marketable securities	26,090,950	11,591,120	1,419,079
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	14,120,838	(36,481,770)	(9,520,867)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on capital leases	(213,991)	(225,406)	(214,801)
Proceeds from issuance of common stock and preferred stock, net		172,641,671	42,448,826
Proceeds from the exercise of warrants and stock options	504,512	12,878,044	2,057,178
NET CASH PROVIDED BY FINANCING ACTIVITIES	290,521	185,294,309	44,291,203
Cash flows from discontinued operations:
Operating cash flows			(354)
Net cash used in discontinued operations:			(354)
NET INCREASE (DECREASE) IN CASH	(51,296,256)	113,396,166	15,737,156
CASH AT BEGINNING OF PERIOD	132,510,610	19,114,444	3,377,288
CASH AT END OF PERIOD	81,214,354	132,510,610	19,114,444
Supplementary disclosures:
Interest paid	14,429	25,635	42,044
3,321,383 shares of Common stock issued to Novartis for asset acquisition	$ 25,000,000
Galloway Limited
Supplementary disclosures:
131,579 shares of Common stock issued to Galloway Limited in settlement of services agreement		$ 500,000
Roche Madison Inc
Supplementary disclosures:
239,894 shares of Common stock issued to Roche for stock and asset acquisition			$ 986,049